47 search results for: chronic inflammation

Itch: The Common Thread in Dermatological Type 2 <b>Inflammation</b> (AD, PN, and CSU)​ - Panel Discussion
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion

Dermatology
Panel discussion exploring how itch differs across AD, PN, and CSU, and how it affects pediatric patients with AD.
View more
Type 2 <b>Inflammation</b> and Neuroimmune Axis Dysregulation in AD, PN, and CSU
expert video

Type 2 Inflammation and Neuroimmune Axis Dysregulation in AD, PN, and CSU

Dermatology
Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.
View more
Contribution of Type 2 Cytokines to <b>Inflammation</b> and Itch in AD, PN, and CSU 
expert video

Contribution of Type 2 Cytokines to Inflammation and Itch in AD, PN, and CSU 

Dermatology
Dr. Marta Ferrer describes the roles of type 2 cytokines in the processes involved in AD, PN, and CSU pathogenesis.
View more
The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management
Infographic

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management

Dermatology
An infographic summarizing the clinical manifestations and pathophysiological processes of PN.
View more
How Does Protective Type 2 Immunity Become Harmful Type 2 <b>Inflammation</b>?
expert video

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

Dermatology
In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.
View more
ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis
Podcast

ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

Dermatology
Professor Lisa Beck explores the chronic and persistent burden of atopic dermatitis (AD) as well as the concept of early intervention in patients with AD.
View more
UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis
expert video

UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis

Dermatology
Dr. Saini summarises the potential role of type 2 cytokines in the pathogensis of CSU.
View more
Mast Cells and the Neuroimmune Axis in CSU
expert video

Mast Cells and the Neuroimmune Axis in CSU

Dermatology
A review of the neuroimmune mechanisms and activation of mast cells that result in itch in CSU.
View more
Disease-Specific Aspects of Itch in AD, PN, and CSU
expert video

Disease-Specific Aspects of Itch in AD, PN, and CSU

Dermatology
Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.
View more
UCARE 2023: Non-Histaminergic Neuronal Sensitization in CSU
expert video

UCARE 2023: Non-Histaminergic Neuronal Sensitization in CSU

Dermatology
Dr. Kim highlights the role of non-histaminergic neuronal sensitization in CSU via cytokines.
View more
UCARE 2023: Immune Cells and Mediators Essential for Driving CSU Pathology
expert video

UCARE 2023: Immune Cells and Mediators Essential for Driving CSU Pathology

Dermatology
Dr. Saini describes immune cells and mediators beyond mast cells that are also essential for helping to drive CSU pathology.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: GreeceChange country/region